Evidence map›Paper›PMID 39500579›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2024

Restoring Compromised Cl

Melissa Serranilla, Jessica C Pressey, Melanie A Woodin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Melissa SerranillaDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario M5S 3G5, Canada.
Jessica C PresseyDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario M5S 3G5, Canada.
Melanie A WoodinDepartment of Cell and Systems Biology, University of Toronto, Toronto, Ontario M5S 3G5, Canada m.woodin@utoronto.ca.ORCID https://orcid.org/0000-0003-2984-8630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder with no cure, characterized by significant neurodegeneration of striatal GABAergic medium spiny neurons (MSNs). Early stages of the disease are characterized by the loss of dopamine 2 receptor-expressing MSNs (D2 MSNs) followed by degeneration of dopamine 1 receptor-expressing MSNs (D1 MSNs), leading to aberrant basal ganglia signaling. While the early degeneration of D2 MSNs and impaired GABAergic transmission are well-documented, potassium chloride cotransporter 2 (KCC2), a key regulator of intracellular chloride (Cl

Indexed as

ChloridesHuntington DiseaseReceptors, Dopamine D2AnimalsCorpus StriatumDisease Models, AnimalFemaleK Cl- CotransportersMaleMiceMice, TransgenicNeuronsReceptors, Dopamine D1SymportersChloridesK Cl- CotransportersReceptors, Dopamine D1Receptors, Dopamine D2SymporterselectrophysiologyGABAHuntington’s diseaseMSNssynaptic inhibition

Identifiers

PMID39500579
PMCPMC11638812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.